Skip to content
ClinCalc Pro
Menu
Iron + folate supplement Pregnancy: §4.6: Ferrograd Folic is indicated for prevention and treatment of iron deficiency anaemia of pregnancy, and prophylaxis of megaloblastic anaemia of pregnancy — pregnancy is the licensed use, and the posology runs throughout pregnancy and the first month of the puerperium. Folic acid is excreted in breast milk.

Ferrous sulfate with folic acid

Brand names: Ferrograd Folic, Slow-Fe Folic

Used in: Anaemia

This combination of ferrous sulfate with folic acid is used mainly for the prevention of iron and folate deficiency in pregnancy.

Adult dose

Dose: Prevention and treatment of iron deficiency anaemia of pregnancy, and prophylaxis of megaloblastic anaemia of pregnancy — adults including the elderly: 1 tablet daily throughout pregnancy and the first month of the puerperium. Take before food. SCOPE: this is the Ferrograd Folic prolonged-release tablet SPC only. Slow-Fe Folic, the other brand named on this page, has its own SPC which was not fetched, and no ferrous sulfate or folic acid content per tablet is stated anywhere in the fetched sections — so no strength is asserted here.
Route: Oral (prolonged-release film-coated tablet). The tablets should not be sucked, chewed or kept in the mouth, but swallowed whole with water. Tablets should be taken before meals or during meals, depending on gastrointestinal tolerance.
Frequency: Once daily
Max: 1 tablet daily is the only dose stated in this SPC; no higher dose is given for any indication or population.
The indication in the dose line is quoted from §4.6, verbatim: 'Ferrograd Folic is indicated for prevention and treatment of iron deficiency anaemia of pregnancy, and prophylaxis of megaloblastic anaemia of pregnancy.' CHILDREN (§4.2), verbatim: 'Not recommended for children under 12 years.' No paediatric dose is stated in this SPC, which is why paedDose is null. FOLIC ACID AND B12: pernicious anaemia is rare in women of childbearing age and is less likely in pregnancy, as vitamin B12 deficiency reduces fertility; however, folic acid at the recommended dosage may obscure the neurological manifestations of pernicious anaemia. ASPIRATION AND SWALLOWING: aspiration of iron sulfate tablets can cause necrosis of the bronchial mucosa, which may result in coughing, haemoptysis, bronchostenosis and/or pulmonary infection, even if aspiration happened days to months before the symptoms occurred; elderly patients and patients with difficulty swallowing should only be treated with iron sulfate tablets after careful evaluation of the individual risk of aspiration, and alternative formulations should be considered. The controlled-release tablet and its inert plastic matrix may cause a safety hazard in some elderly or other patients suffering from delayed intestinal transit. Due to the risk of mouth ulcerations and tooth discolouration, tablets must not be sucked, chewed or kept in the mouth. INTERACTION SPACING (§4.5): iron inhibits the absorption of tetracyclines and tetracycline inhibits the absorption of iron — if both must be given, tetracycline should be administered three hours after or two hours before oral iron. Oral iron should not be taken within one hour before or two hours after antacids, calcium supplements (carbonate or phosphate), tea, coffee, eggs, food or medicines containing bicarbonates, carbonates, oxalates or phosphates, milk or milk products, wholegrain breads and cereals, or dietary fibre. Iron also interacts with magnesium trisilicate, trientine and zinc salts (absorption of all may be impaired) and may interfere with the oral absorption of some quinolone anti-infectives. Some sections of the product information we used were incomplete — check the full SPC. EXCIPIENTS: contains lactose — patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine. STORAGE WARNING: keep out of children's reach; acute iron poisoning occurs rarely in adults but could happen if children swallow this medication, and overdose may be fatal.

Dose independently re-sourced from UK Summary of Product Characteristics (SPC) via the eMC; US FDA prescribing information (openFDA / DailyMed) — cross-check; US labelling may differ from UK — clinician-reviewed. Always confirm against the product SmPC and your local formulary before prescribing.

Contraindications

  • Megaloblastic anaemia due to primary vitamin B12 deficiency
  • Pernicious anaemia
  • Intestinal diverticular disease or any intestinal obstruction
  • Haemochromatosis and haemosiderosis (iron preparations are contraindicated)
  • Patients receiving repeated blood transfusions
  • Concomitant use with parenteral iron therapy (oral iron preparations are contraindicated when used concomitantly)
  • Hypersensitivity to folic acid (rare)

Side effects

  • Nausea, vomiting, abdominal pain or discomfort, blackening of stools, diarrhoea and/or constipation — the side effects reported are similar to those of conventional oral iron preparations, but the incidence is less owing to the prolonged-release nature of the formulation
  • Allergic reaction — isolated cases reported, ranging from rash to anaphylaxis; allergy is more common in people who are allergic to aspirin
  • Allergic sensitisation has been reported following both oral and parenteral administration of folic acid
  • Bronchial stenosis (see the aspiration warning in §4.4)
  • Mouth ulceration (post-marketing, frequency not known) — in the context of incorrect administration, when the tablets are chewed, sucked or kept in the mouth
  • Oesophageal lesions or bronchial necrosis in elderly patients and patients with deglutition disorders, in case of false route

Monitoring

  • Exclude primary vitamin B12 deficiency and pernicious anaemia before starting — folic acid at the recommended dosage may obscure the neurological manifestations of pernicious anaemia
  • Be aware that iron preparations colour the faeces black, which may interfere with tests used for the detection of occult blood in the stools; the guaiac test occasionally yields false positive results
  • Evaluate the individual risk of aspiration in elderly patients and patients with swallowing difficulty before using iron sulfate tablets, and consider alternative formulations
  • Advise patients to seek medical attention in case of suspected aspiration
  • Consider the safety hazard of the controlled-release tablet and its inert plastic matrix in elderly or other patients with delayed intestinal transit

Clinical monograph

How it works

Ferrous sulfate supplies absorbable iron for haemoglobin synthesis, while folic acid provides the folate required for DNA synthesis and normal red cell maturation, together supporting erythropoiesis and neural tube development.

Prescribing in practice

  • The folic acid dose in these prophylactic combinations is intended for prevention and is insufficient for established megaloblastic anaemia or for high-risk neural tube defect prophylaxis, which require dedicated higher-dose folic acid.
  • Folic acid can mask the haematological signs of vitamin B12 deficiency while allowing neurological damage to progress, so exclude B12 deficiency before relying on folate alone.
  • Standard iron absorption interactions apply, so separate from tea, antacids, calcium and chelated drugs such as tetracyclines and levothyroxine.

Monitoring

Monitor haemoglobin during pregnancy and review the formulation if treatment of an established anaemia rather than prophylaxis is required.

Counselling the patient

  • This product is for preventing iron and folate deficiency, usually in pregnancy.
  • Stools may turn black, which is harmless.
  • Keep out of reach of children because of iron overdose risk.

Evidence & guidelines

NICE advises folic acid supplementation before and in early pregnancy to reduce neural tube defect risk, with combination iron-folate products used for routine antenatal prophylaxis.

Reference: NICE CG62; Confirm identity and dosing against the manufacturer SPC (eMC) and NICE. Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.